Paris-based TISSIUM, a medtech company developing biomorphic programmable polymers for tissue reconstruction, announced that it has closed €50M in a Series D round of funding.
The financing comes from new and existing international investors, including Fonds Stratégique des Transitions, managed by ISALT, Merieux Developpement and returning Cathay Health, Credit Mutuel Innovation, and Sofinnova Partners.
TISSIUM claims this latest round of funding comes at a time of significant milestones for the company, including its ongoing first-in-human study on its first nerve repair product — COAPTIUM Connect, in Australia and multiple ongoing regulatory activities.
This funding will enable the French company to continue executing its development plan, supporting the commercialization of its initial nerve and hernia repair products.
Furthermore, the capital will facilitate the expansion of its’s product pipeline and platform.
TISSIUM intends to advance the development and commercialization of products derived from its unique biopolymer platform.
According to the company, its products will address multiple unmet clinical needs, including atraumatic tissue repair and reconstruction.
At the core of TISSIUM’s technology platform lies a proprietary family of fully biosynthetic, biomorphic, and programmable polymers.
Read more on Tech Gist Africa: